Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

The mammalian target of rapamycin complex 1 (mTORC1) is hyperactive in many human cancers and in tuberous sclerosis complex (TSC). Autophagy, a key mTORC1-targeted process, is a critical determinant of metabolic homeostasis. Metabolomic profiling was performed to elucidate the cellular consequences of autophagy dysregulation under conditions of hyperactive mTORC1. It was discovered that TSC2-null cells have distinctive autophagy-dependent pentose phosphate pathway (PPP) alterations. This was accompanied by enhanced glucose uptake and utilization, decreased mitochondrial oxygen consumption, and increased mitochondrial reactive oxygen species (ROS) production. Importantly, these findings revealed that the PPP is a key autophagy-dependent compensatory metabolic mechanism. Furthermore, PPP inhibition with 6-aminonicotinamide (6-AN) in combination with autophagy inhibition suppressed proliferation and prompted the activation of NF-κB and CASP1 in TSC2-deficient, but not TSC2-proficient cells. These data demonstrate that TSC2-deficient cells can be therapeutically targeted, without mTORC1 inhibitors, by focusing on their metabolic vulnerabilities. Implications: This study provides proof-of-concept that therapeutic targeting of diseases with hyperactive mTORC1 can be achieved without the application of mTORC1 inhibitors. Mol Cancer Res; 12(1); 48–57. ©2013 AACR.

[1]  E. Roach,et al.  Tuberous sclerosis complex. , 2015, Handbook of clinical neurology.

[2]  P. Vandenabeele,et al.  Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide , 2012, Anti-cancer drugs.

[3]  E. White.  Deconvoluting the context-dependent role for autophagy in cancer , 2012, Nature Reviews Cancer.

[4]  A. Sepulveda,et al.  Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency , 2012, Proceedings of the National Academy of Sciences.

[5]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[6]  S. Akira,et al.  Mitochondrial DNA That Escapes from Autophagy Causes Inflammation and Heart Failure , 2012, Nature.

[7]  Richard A. Flavell,et al.  Inflammasomes in health and disease , 2012, Nature.

[8]  H. Ke,et al.  Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13 , 2011, Cell.

[9]  D. Kwiatkowski,et al.  Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent , 2011, Proceedings of the National Academy of Sciences.

[10]  Ana Maria Cuervo,et al.  Autophagy in the cellular energetic balance. , 2011, Cell metabolism.

[11]  S. Ryter,et al.  Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. , 2011, Nature immunology.

[12]  H. Coller,et al.  Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. , 2011, Genes & development.

[13]  Michael J Morgan,et al.  Crosstalk of reactive oxygen species and NF-κB signaling , 2011, Cell Research.

[14]  H. Ke,et al.  Beclin 1 Controls the Levels of p 53 by Regulating the Deubiquitination Activity of USP 10 and USP 13 , 2011 .

[15]  Qicheng Ma,et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.

[16]  Sang Gyun Kim,et al.  Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. , 2010, Molecular cell.

[17]  W. Du,et al.  Specific killing of Rb mutant cancer cells by inactivating TSC2. , 2010, Cancer cell.

[18]  H. Lane,et al.  Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis , 2009, Molecular Cancer.

[19]  S. Akira,et al.  Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production , 2008, Nature.

[20]  P. Puigserver,et al.  Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC‐1α , 2007, The EMBO journal.

[21]  D. Kwiatkowski,et al.  Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin. , 2005, Cancer research.

[22]  D. Waxman,et al.  Antitumor Activity of Methoxymorpholinyl Doxorubicin: Potentiation by Cytochrome P450 3A Metabolism , 2005, Molecular Pharmacology.

[23]  J. Hothersall,et al.  Inhibition of NADPH supply by 6‐aminonicotinamide: effect on glutathione, nitric oxide and superoxide in J774 cells , 1998, FEBS letters.